MALDI Biotyper® MBT STAR®-Cepha RUO Kit

The Bruker MALDI Biotyper® MBT STAR®-Cepha RUO Kit is designed to combat resistance to third-generation cephalosporins by identifying the enzymatic hydrolysis of the beta-lactam ring in cephalosporin antibiotics. It supports the detection of extended-spectrum beta-lactamases (ESBL) and AmpC beta-lactamases, offering critical diagnostic insights into multidrug-resistant (MDR) Gram-negative bacteria.

Key Features

1. Rapid Resistance Detection:
   • Swiftly identifies cephalosporin resistance directly from positive blood cultures or isolated colonies.
   • Results are available within 30-60 minutes, enabling prompt decision-making.
2. Comprehensive Beta-Lactamase Detection:
   • ESBL: Detects plasmid-mediated resistance enzymes such as TEM, SHV, and CTX-M.
   • AmpC: Identifies chromosomal and plasmid-mediated resistance genes, including AmpC, FOX, LAT, DHA, and CMY.
3. Automated Analysis:
   • The MBT HT STAR®-BL module simplifies data interpretation with color-coded indicators and clear visualization of results.
4. Flexible Workflow:
   • Compatible with both positive blood culture pellets and plate cultures.
   • Integrates seamlessly with the MALDI Biotyper® platform for a unified diagnostic solution.

Applications

1. Cephalosporin Resistance Monitoring:
   • Identifies resistance mechanisms in clinical isolates, guiding therapy for infections caused by resistant pathogens.
2. Hospital Infection Control:
   • Detects resistant Gram-negative Enterobacterales to prevent the spread of MDR organisms in healthcare settings.
3. Sepsis Diagnostics:
   • Provides rapid resistance profiling after a positive blood culture alert, improving antimicrobial stewardship.
4. Multidrug-Resistant Pathogen Surveillance:
   • Tracks the emergence and prevalence of ESBL- and AmpC-producing bacteria in clinical and research settings.

Workflow

1. Sample Preparation:
   • A positive blood culture or isolated bacterial colony is incubated with a beta-lactam antibiotic (e.g., third-generation cephalosporins).
2. Mass Spectrometry Analysis:
   • After incubation, the sample is analyzed using the MALDI Biotyper®, which measures the mass shift caused by beta-lactam ring hydrolysis.
3. Data Interpretation:
   • The MBT HT STAR®-BL software module computes the ratio of hydrolyzed to intact antibiotic molecules, presenting results in an easy-to-read, color-coded format.
4. Report Generation:
   • Users receive a comprehensive report detailing enzyme activity status and resistance profiles.

Use Cases

1. Detection of ESBL Resistance:
   • Example: Identifying Escherichia coli or Klebsiella pneumoniae isolates with CTX-M-mediated resistance in bloodstream infections.
2. AmpC Beta-Lactamase Surveillance:
   • Example: Monitoring chromosomal AmpC resistance in Enterobacter cloacae during an outbreak.
3. Therapeutic Guidance:
   • Supports clinicians in selecting effective antibiotics, minimizing treatment failures, and preventing overuse of broad-spectrum drugs.

Benefits

• Speed: Results are available much faster than conventional phenotypic methods.
• Accuracy: Provides high confidence in detecting specific resistance mechanisms.
• Ease of Use: Automated software simplifies analysis and reporting.
• Cost-Effectiveness: Combines identification and resistance testing on a single MALDI-TOF platform.
• Enhanced Stewardship: Improves patient outcomes by promoting targeted therapy.

By enabling rapid detection of third-generation cephalosporin resistance, the MBT STAR®-Cepha IVD Kit empowers microbiology labs to improve diagnostic efficiency and combat the growing threat of antibiotic resistance.